Literature DB >> 34282400

Efficacy and toxic effect associated with subretinal tissue plasminogen activator injection in treating submacular hemorrhage.

Jia-Ning Ren1, Jie Peng1, Yu Xu1, Qi Zhang1, Shuang-Shuang Chen1, Pei-Quan Zhao1.   

Abstract

Entities:  

Year:  2021        PMID： 34282400      PMCID： PMC8243174          DOI： 10.18240/ijo.2021.07.23

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN： 2222-3959            Impact factor:   1.779


× No keyword cloud information.
  5 in total

1.  Pharmacokinetics of the recombinant thrombolytic agents: what is the clinical significance of their different pharmacokinetic parameters?

Authors:  A Cohen
Journal:  BioDrugs       Date:  1999-02       Impact factor: 5.807

2.  Evaluation of a commercial recombinant tissue-type plasminogen activator preparation in the subretinal space of the cat.

Authors:  J D Benner; L S Morse; C A Toth; M B Landers; L M Hjelmeland
Journal:  Arch Ophthalmol       Date:  1991-12

3.  Natural history of macular subretinal hemorrhage in age-related macular degeneration.

Authors:  A Scupola; G Coscas; G Soubrane; E Balestrazzi
Journal:  Ophthalmologica       Date:  1999       Impact factor: 3.250

4.  A New Method of Subretinal Injection of Tissue Plasminogen Activator and Air in Patients With Submacular Hemorrhage.

Authors:  Fernando J D Novelli; Rony C Preti; Mario L R Monteiro; Mario J Nóbrega; Walter Y Takahashi
Journal:  Retina       Date:  2017-08       Impact factor: 4.256

5.  Submacular hemorrhage secondary to age-related macular degeneration managed with vitrectomy, subretinal injection of tissue plasminogen activator, hemorrhage displacement with liquid perfluorocarbon, gas tamponade, and face-down positioning.

Authors:  Abdullah Ozkaya; Gurkan Erdogan; Hatice Nur Tarakcioglu
Journal:  Saudi J Ophthalmol       Date:  2018-08-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.